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Although the prognosis for patients with early-stage breast cancer
has improved, the therapeutic options for patients with locally
advanced and metastatic disease are limited. To improve the
treatment of these patients, the molecular mechanisms underlying
breast cancer invasion and metastasis must be understood. In this
study, we report that signaling through the G12 family of hetero-
trimeric G proteins (G12 and G13) promotes breast cancer cell
invasion. Moreover, we demonstrate that inhibition of G12 sig-
naling reduces the metastatic dissemination of breast cancer cells
in vivo. Finally, we demonstrate that the expression of G12 is
significantly up-regulated in the earliest stages of breast cancer,
implying that amplification of G12 signaling may be an early event
in breast cancer progression. Taken together, these observations
identify the G12 family proteins as important regulators of breast
cancer invasion and suggest that these proteins may be targeted
to limit invasion- and metastasis-induced patient morbidity and
mortality.
cadherin  Rho  G protein-coupled receptor
Heterotrimeric guanine nucleotide-binding proteins (G pro-teins) transmit extracellular signals from cell surface G
protein-coupled receptors to intracellular effector molecules (1).
Because of the array of extracellular signals that activate them and
the large number of intracellular targets to which they signal,
heterotrimeric G proteins have been implicated in many physiologic
and pathophysiologic processes (2, 3). Heterotrimeric G proteins
are classified into four subfamilies: Gs, Gi, Gq, and G12. The G12
subfamily has been of particular interest to cancer biologists since
its discovery. Originally identified because of its sequence similarity
to other G protein -subunits (4) and as a sarcoma-associated
oncogene (5), G12 and its sister protein G13 are the only
heterotrimeric G proteins that are able to transform fibroblasts
when overexpressed in their wild-type form (5, 6). As a result, it has
been suggested that G12 signaling may promote tumorigenesis and
tumor growth (7). However, to date, no role for G12 signaling in
human cancers has been demonstrated.
We sought to explore the role of the G12 proteins in breast
cancer, which, besides skin cancer, is the most common form of
cancer in the world. Surprisingly, we found that activation of the
G12 pathway did not promote growth in breast cancer cells. Instead,
activation of G12 signaling induced a striking increase in breast
cancer cell invasion in vitro and the inhibition of G12 signaling
significantly reduced breast cancer metastasis in vivo. In addition,
G12 expression was found to be markedly up-regulated in human
breast cancer specimens, suggesting that G12 signaling is an im-
portant regulator of breast cancer invasion and metastasis.
Results
G12 Signaling Does Not Promote the Growth or Transformation of
Breast Cancer Cells. To assess the biological significance of G12
signaling in breast cancer, we first examined the effects of modu-
lating the activity of G12 proteins on breast cancer cell proliferation.
To stimulate G12 signaling in breast cancer cells, we expressed the
constitutively active forms of G12 [G12(Q231L)] and G13
[G13(Q226L)] in several cell lines (Fig. 1A). Because most recep-
tors that activate the G12 proteins also activate the Gq proteins (8),
we also expressed the constitutively active form of Gq
[Gq(Q209L)] in these lines as a control (Fig. 1A). To inhibit G12
signaling in breast cancer cells, we expressed the regulator of G
protein signaling (RGS) domain of the p115 Rho-GEF (p115-RGS)
(Fig. 1C). The expression of specific RGS domains is a well
characterized method to selectively block signaling through differ-
ent subfamilies of heterotrimeric G proteins (9–11), and the
p115-RGS domain selectively binds and inactivates members of the
G12 family (9, 10). In addition, to inhibit Gq signaling in breast
cancer cells, we expressed RGS2, an RGS that selectively binds and
inactivates members of the Gq family (11) (Fig. 1C).
In contrast to previous studies using nontransformed cells (5, 6,
12, 13), expression of the activated forms of G12 and G13 did not
promote, and in some cases even inhibited, in vitro proliferation of
human breast cancer lines under either anchorage-dependent (Fig.
5A, which is published as supporting information on the PNAS web
site) or -independent conditions (Fig. 5B). Furthermore, expression
of p115-RGS and RGS2 had little to no effect on the cell prolif-
eration (Fig. 5). Thus, although, in some cell types, G12 and G13
may be important promoters of cell growth, they do not appear to
promote breast cancer cell growth.
G12 Signaling Promotes Breast Cancer Cell Invasion. Notably, in
addition to promoting cell growth, many of the signaling pathways
downstream of the G12 and G13 have been implicated in cancer
cell invasion and metastasis (7, 14). Therefore, we next sought to
determine whether G12 proteins affect breast cancer invasion and
metastasis. First, we examined the impact of G12 signaling on breast
cancer cell invasion by using the transwell invasion assay (15).
Expression of activated G12 or activated G13 in T47D, BT549,
MDA-MB-231, and 4T1 (Fig. 1B) breast cancer cells significantly
increased cellular invasion. In contrast, expression of activated Gq
had no effect (Fig. 1B). Thrombin stimulates cancer cell invasion
and metastasis through protease-activated receptor-1 (PAR-1) (16,
17), and stimulation of PAR-1 activates both G12 and Gq proteins
(8). Thrombin-induced invasion of the BT549 and MDA-MB-231
cell lines was blocked by inhibition of G12 signaling (by expression
of p115-RGS), whereas the inhibition of Gq signaling (by expres-
sion of RGS2) had no effect (Fig. 1D). As an additional control, an
adenovirus was engineered to express a disabled form of p115-
RGS, p115-RGS(E29K). This point mutant of the p115-RGS
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neither binds to nor functions as a GTPase-activating protein for
the G12 proteins and, thus, does not affect G12 signaling (18).
Expression of this protein had no effect on thrombin-induced cell
invasion (Fig. 1D), indicating that the inhibitory effects of p115-
RGS are the result of its ability to bind and inactivate the G12
proteins. To determine whether these results were specific to
PAR-1, we also assessed the impact of thromboxane A2 receptor
stimulation on cancer cell invasion. Stimulation of this receptor,
which also couples to both G12 and Gq proteins, markedly en-
hanced invasion of the MD-MBA-231 cells, and this effect was
blocked by expression of p115-RGS but not RGS2 or the p115-
RGS(E29K) (Fig. 1E). These data provide convincing evidence
that stimulation of the G12 proteins is capable of promoting
invasion of breast cancer cells.
The Role of Rho G Proteins in G12-Promoted Breast Cancer Cell
Invasion. In most cell types, stimulation of the G12 proteins results
in the activation of the RhoABC family of monomeric G proteins
(7). Many studies have demonstrated that the Rho family of
proteins plays a significant role in breast cancer invasion (19). Thus,
we examined the role of Rho signaling in G12-induced breast
cancer invasion. First, we confirmed that the G12 proteins are able
to activate Rho in breast cancer cell lines. Expression of the
activated forms of G12 and G13 in the MDA-MB-231 (Fig. 2A),
T47D (Fig. 6A, which is published as supporting information on the
PNAS web site), and 4T1 (Fig. 6B) cell lines induced a significant
increase in the levels of GTP-bound Rho. Interestingly and con-
sistent with recent reports (20), the activated form of Gq also
induced a small increase in the level of GTP-bound Rho (Fig. 2A).
In addition, stimulation of the MDA-MB-231 cell line with throm-
bin resulted in 5-fold increase in the levels of GTP-bound Rho
(Fig. 2B). This stimulation was inhibited by expression of the
p115-RGS but not by expression of the p115-RGS(E29K) or RGS2
(Fig. 2B). Taken together these data confirm that G12 signaling is
able to activate the Rho proteins in breast cancer cells.
Next we sought to determine the contribution of signaling
through the Rho proteins in G12-induced breast cancer cell inva-
sion. Treatment of the MDA-MB-231, BT549, T47D (Fig. 2C), and
4T1 (Fig. 6C) cell lines with C3 toxin, a specific and irreversible
inhibitor of RhoABC, blocked G12(QL)-induced invasion.
These data demonstrate that Rho signaling is required for G12-
stimulated invasion. However, given that C3 toxin treatment of
these breast cancer cells also reduced basal invasion, it was not clear
from these data whether G12-stimulated invasion simply requires
Rho signaling or whether G12 must activate Rho to induce invasion.
To address these possibilities, we used a mutant form of G12
[G12 (244–249)] that is unable to activate Rho but is still able to
interact with other putative G12 effectors (21). Expression of the
constitutively active form of this protein [G12QL (244–249)] in
the MDA-MB-231, BT549 (Fig. 2D), or 4T1 (Fig. 6D) cell lines did
not promote invasion. These results suggest that that G12 must
activate the Rho pathway to induce invasion in these cell types.
Interestingly, however, when G12QL (244–249) was expressed
in T47D cell line, although it did not activate Rho (Fig. 6A), it did
induce a small but significant increase in invasion (Fig. 2D). This
finding suggests that, although maximal G12-stimulated breast
Fig. 1. G12 signaling promotes breast cancer cell invasion. (A) Expression of the activated forms of G12 (G12QL) and G13 (G13QL) but not Gq (GqQL)
induces breast cancer cell invasion in vitro. Cells were transduced with the indicated adenovirus, starved for 18 h, and then allowed to invade growth-factor-
reduced Matrigel (T47D, MDA-MB-231, and BT549) or collagen-coated (4T1) transwell filters for 30 h. (B) Immunoblot analysis showing expression levels of G12,
G13, and Gq in the T47D cell line after infection with the indicated adenovirus. Similar expression was observed in the other cells types. (C and D) Expression
of p115-RGS blocks thrombin (C) and thromboxane A2-induced (U46619) (D) invasion of breast cancer cells, whereas expression of RGS2 or expression of an
inactive form of the p115-RGS, p115-RGS(E29K), has no effect. Cells were transduced with the indicated adenovirus, starved for 18 h, then allowed to invade
growth-factor-reduced Matrigel-coated transwell filters for 30 h in the presence of 1 unitml thrombin (A), 100 nM U46619 (B), or vehicle control. (E) Immunoblot
analysis showing expression levels of p115-RGS, p115-RGS(E29K), and RGS2 in the MDA-MB-231 cell line after infection with the indicated adenovirus. Similar
expression was observed in the BT549 cells. (A, C, and D) Experiments were performed in triplicate, and the results are presented as the fold increase over
vehicle-treated GFP control. All results are presented as mean  SE from a single experiment. All experiments were performed at least three times. *, P  0.05
as determined by paired Student t test.
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cancer invasion requires Rho activation, in some cell types G12
may be able to promote invasion in a Rho-independent pathways
(7, 14, 22).
G12 Signaling Promotes Cancer Metastasis. Although in vitro assays
can provide mechanistic insight into cancer progression and spread,
the complexity of the metastatic process demands in vivo experi-
mentation for accurate modeling (23). For this reason, we decided
to employ the 4T1 cell line (24). When implanted in the mammary
fat pad of recipient mice, 4T1 cells grow and metastasize in a
manner similar to that of human breast cancer (24–26). We
engineered 4T1 cells to stably express p115-RGS, p115-RGS
(E29K), or RGS2 and implanted these cells in the mammary fat pad
of 6-week-old BALBc mice. Consistent with our in vitro results, the
expression of p115-RGS, p115-RGS(E29K), or RGS2 had no
measurable effect on the rate of tumor growth compared with
control tumors (Fig. 7, which is published as supporting information
on the PNAS web site). Moreover, the inhibition of G12 or Gq
signaling led to no detectable differences among the tumors upon
histopathologic examination in proliferative index, as determined
by Ki-67 staining; rate of apoptosis, as determined by TUNEL
staining; nor vascular density, as determined by CD31 staining
(data not shown). Thus, inhibition of G12 signaling had no mea-
surable effect on the growth of the 4T1 primary tumors.
To track the metastatic spread of the 4T1 cells in live animals, the
4T1 cells were also engineered to stably express firefly luciferase
(26, 27). After 3 weeks of growth, the primary 4T1 tumors were
removed and metastasis was visualized with the IVIS imaging
system (26). We defined a metastatic event as any detectable
luciferase signal above background and away from the primary
tumor site to prevent confusion resulting from primary tumor
recurrence. Strikingly, inhibition of G12 signaling with p115-RGS
(n  16) resulted in a significant increase in metastasis-free survival
compared with the p115-RGS(E29K) (n  5; P  0.0013), RGS2
(n  11; P  0.001), or vector control (n  17; P  0.0001) groups
(Fig. 3A). Moreover, inhibition of G12 signaling with p115-RGS
(n  16) resulted in a significant increase in overall survival
compared with the p115-RGS(E29K) (n  5; P  0.002), RGS2
(n  11; P  0.001), and vector control (n  17; P  0.0001) groups
(Fig. 3B). These data indicate that G12 signaling is required for
efficient metastatic spread of 4T1 cancer cells in vivo.
To further dissect the role of G12 signaling in metastasis, we
injected 4T1 cells expressing the p115-RGS (n  5) or vector
control (n  6) into the tail vein of BALBc mice (23, 26). When
seeded directly into the blood stream in this manner, no difference
was seen in the metastatic dissemination of the cancer cells (Fig. 8A,
which is published as supporting information on the PNAS web site)
or the overall survival of the mice (Fig. 8B). These results imply that
G12 function is not required in the later steps of the metastatic
cascade. Taken together, these in vivo results correlate well with our
in vitro findings and suggest that G12 signaling promotes metastasis
by stimulating invasion by the primary tumor.
The G12 Protein Is Up-Regulated in Carcinoma of the Breast. Because
G12 signaling promoted breast cancer cell invasion both in vitro and
in vivo, we sought to elucidate the physiological relevance of the
and the results are presented as the fold increase over that observed with GFP
control. All experiments were performed at least three times. All results are
presented as mean  SE. *, P  0.05 as determined by paired Student t test. (D)
The effect of the expression of G12QL (244–249), a mutant of G12QL that
is functionally uncoupled from the Rho axis but is still able to interact with
other putative G12 effectors, on breast cancer cell invasion. Experiments were
performed as in C. Experiments were preformed in duplicate, and the results
are presented as the fold increase over that observed with GFP control. All
experiments were performed at least three times. All results are presented as
mean  SE. *, P  0.05 as determined by paired Student t test.
Fig. 2. G12 signaling is able to promote breast cancer cell invasion through
the activation of the Rho family of monomeric G proteins. (A) Expression of
G12QL and G13QL induces RhoA activation in the MDA-MB-231 cell line.
Cells were transduced with the indicated adenovirus and then starved for 18 h.
Cells were lysed, and the lysates were subjected to pull-down assays using a
GST fusion of the activated RhoA-binding domain of rhotekin. Levels of
precipitated RhoA were determined by immunoblot analysis using anti-RhoA
antibody. Levels of total RhoA, G12, G13, and Gq also were determined.
All lanes are representative of two or more separate experiments. (B) Throm-
bin-stimulated RhoA activation in MDA-MB-231 cells is inhibited by expression
of p115-RGS but not by expression of RGS2 or p115-RGS(E29K). Cells were
transduced with the indicated adenovirus, starved for 18 h, and then stimu-
lated with thrombin (1 unitml) or a vehicle control for 5 min. Levels of
activated Rho were determined as in A. Levels of total RhoA, myc-p115-RGS,
and RGS2 also were determined. All lanes are representative of two or more
separate experiments. (C) G12-mediated breast cancer cell invasion requires
the activity of the Rho family of G proteins. Cells were transduced with the
indicated adenovirus, starved for 18 h in the presence and absence of C3 toxin
as indicated, and then allowed to invade growth-factor-reduced Matrigel-
coated transwell filters for 30 h. Experiments were performed in duplicate,











G12 proteins in tumor invasion and metastasis by assessing its
expression in breast biopsies obtained from patients with breast
cancer. Immunohistochemical detection of G12 in sections of both
ductal carcinoma of the breast and lobular carcinoma of the breast
revealed that breast cancer cells consistently expressed higher levels
of G12 compared with benign breast epithelial cells within the
same tissue section (Fig. 4). G12 staining could be completely
blocked by preincubation of the antibody with its blocking peptide,
demonstrating antibody specificity (Fig. 9, which is published as
supporting information on the PNAS web site). Interestingly, no
increase in Gq expression was seen in these specimens (Fig. 10,
which is published as supporting information on the PNAS web
site), suggesting that this elevated expression is specific to G12.
To broaden the analysis of G12 expression in primary human
cancers, a tissue microarray of 80 breast biopsy samples containing
ductal carcinoma in situ and invasive carcinoma with matched
benign breast tissue was stained for G12 expression and graded
0–4 based on signal intensity. This analysis demonstrated that
G12 expression is significantly increased in both in situ and
invasive ductal carcinomas of the breast (staining intensity: normal
breast epithelium, 1.2  0.1; ductal carcinoma in situ, 2.3  0.4; and
invasive ductal carcinoma, 2.1  0.1) (Table 1). These data provide
evidence that G12 expression is increased early in breast cancer
progression, before the tumors become invasive. Thus, these find-
ings are consistent with our results showing G12 signaling as an
important regulator of breast cancer invasion and suggest that G12
up-regulation may serve as an early marker for the development of
a more aggressive, invasive phenotype.
Discussion
In this report, we demonstrate that G12 is markedly up-regulated
in adenocarcinoma of the breast and identify G12 signaling as an
important regulator of breast cancer invasion and metastasis.
Previous studies have shown that G12 signaling is able to promote
cell growth in some cell lines (5, 6, 12, 13). Thus, our results that G12
signaling did not promote tumor cell growth were surprising.
However, it is interesting to note that much of the previous work on
the mitogenic effects of G12 signaling was done in nontransformed,
fibroblast-derived cell lines (5, 6, 12, 13). Because our studies used
transformed cells of epithelial origin, it is possible that the discrep-
ancy results from fundamental differences between normal and
transformed cells andor between cells of mesenchymal and epi-
thelial origin. Thus, although it is clear that in some cell types G12
and G13 may be important promoters of cell growth, they do not
appear to promote breast cancer cell growth.
In contrast to the data on proliferation, this study provides
compelling evidence for a role for G12 signaling in breast cancer
cell invasion. Activation of the pathway by expression of the
activated forms of the G12 proteins or by receptor stimulation of the
endogenous G12 proteins resulted in a significant increase in the in
vitro invasiveness of several breast cancer cell lines. Although this
finding is novel in the field of cancer biology, studies in other
systems have implicated G12 signaling in the related biologies of cell
migration and extracellular matrix adhesion. In particular, studies in
neutrophils have demonstrated that the G12 proteins are critically
Fig. 3. Inhibition of G12 signaling reduces metastatic dissemination of the
4T1 cell line orthotopically implanted in the mouse mammary fat pad. The
mammary fat pads of BALBc mice were injected with 5  105 4T1-Luc cells
(red; n  17), 4T1-Luc cells expressing p115-RGS (blue; n  16), 4T1-Luc cells
expressing RGS2 (yellow; n  11), or 4T1-Luc cells expressing p115-RGS(E29K)
(green; n  5). Tumors were grown for 21 days and then excised as described
in Methods and Materials. (A) Metastasis-free survival after primary tumor
resection. A metastatic event was defined as any detectable bioluminescent
signal above background away from the primary site. Mice that received
p115-RGS-expressing 4T1 cells had significantly longer metastasis-free survival
times than did mice that received control 4T1 cells (P  0.0001), RGS2-
expressing cells (P  0.001), or p115-RGS(E29K)-expressing cells (P  0.0013).
Statistical analyses were performed by using the log-rank test. (B) Overall
mouse survival. Mice that received p115-RGS-expressing 4T1 cells survived
significantly longer than did mice that received control 4T1 cells (P  0.0001),
RGS2-expressing cells (P  0.001), or p115-RGS(E29K)-expressing cells (P 
0.002). Statistical analyses were performed by using the log-rank test.
Fig. 4. G12 protein levels are up-regulated in carcinoma in situ and in
invasive adenocarcinoma of the breast. Sections of formalin-fixed paraffin-
embedded breast tissue were stained for G12 with anti-G12 anti-sera (Santa
Cruz Biotechnology) as described in Methods and Materials. Original images
were taken with a 40 objective. (A and B) Benign breast tissue. (C) Ductal
carcinoma in situ of the breast. (D) Lobular carcinoma in situ of the breast. (E)
Section containing benign breast epithelium, carcinoma in situ, and invasive
ductal carcinoma of the breast. (F) Section containing both benign breast
epithelium and invasive lobular carcinoma of the breast. (E and F) Arrowheads
indicate cancer; arrows indicate benign epithelium.
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important in establishing cell polarity (28). Developmental studies
in Drosophila (29) and in zebrafish (30) have demonstrated that G12
signaling is critical for cell migration during gastrulation. Further-
more, genetic ablation of G13 in mice impairs the organization of
the vascular system (31). Embryonic fibroblasts cultured from these
mice display a reduced chemokinetic response to several G protein-
coupled receptor ligands, and Offermanns et al. speculated that this
defect in cell migration may underlie the failed angiogenesis (31).
Although the results from the in vitro assays used in this study
strongly suggest a role for G12 in tumor invasion, the most
compelling data supporting this hypothesis comes from the in vivo
studies with the 4T1 mammary carcinoma line. In these experi-
ments, inhibition of G12 signaling resulted in a significant decrease
in metastasis from the mammary fat pad but did not affect either
primary tumor growth or seeding of the lungs when cancer cells
were introduced via the tail vein. Recent evidence suggests that 4T1
cells metastasize to the lung and, possibly, other organs by embo-
lizing to the capillary bed and then growing in the intravascular
space (32). This phenomenon of metastasis without extravasation
does not appear to be limited to the 4T1 cells (32). However, exiting
the vascular bed does appear to be a requirement for the metastasis
of other cell types (23). Therefore, it is possible that, for other tumor
types and at other sites of distant metastasis, G12 signaling also
plays a role in these later stages of metastasis. Nevertheless, given
that we saw no difference in metastatic potential of the 4T1 cells
expressing p115-RGS and control cells when they were seeded into
the blood stream directly, the difference in the metastatic dissem-
ination of these cells from the mammary fat pad must reflect a
disparity in the rate that cells are shed from the primary tumors.
Thus, G12 signaling appears to promote cancer metastasis by
stimulating tumor cell invasion and entry into the blood stream.
The findings that blockade of G12 signaling dramatically impacts
metastatic behavior of cancer cells prompted us to examine the
expression the G12 proteins in tissue samples from patients with
adenocarcinoma of the breast. We found that G12 expression was
significantly higher in situ and in invasive carcinomas compared
with normal epithelium. This finding is consistent with a previous
report suggesting that G12 and G13 expression is elevated in cell
lines derived from metastatic human breast, prostate, and colon
cancers (33). This up-regulation of G12 in intraepithelial neo-
plasms also is similar to what was previously reported for receptors
that couple to the G12 protein (16, 34) and the increased expression
of the Rho proteins observed at this point or later in cancer
development (16, 35). Thus, it appears that the G12 signaling
pathway is up-regulated as an invasion-promoting signaling unit as
breast cancer progresses to an invasive phenotype. Overall, the data
presented here define G12 signaling as a key promoter of breast
cancer invasion. Furthermore, from a clinical perspective, these
studies suggest that targeted inhibition of G12 signaling may
provide effective therapies to reduce local invasion, slow metastasis,
and reduce cancer mortality.
Materials and Methods
Cell Lines, Reagents, and Antibodies. All human cell lines were
obtained from the American Type Culture Collection and grown
under the recommended conditions. The 4T1 cell line (a generous
gift from Fred Miller, Barbara Ann Karmanos Cancer Center,
Detroit) was maintained in DMEM supplemented with 10% FCS.
Recombinant human thrombin was from Enzyme Research Lab-
oratories (South Bend, IN), and U46619 and tetanolysin were from
Biomol (Plymouth Meeting, PA). Growth-factor-reduced Matrigel
was from BD Biosciences (Bedford, MA), and the fibronectin from
bovine plasma was from Sigma. GST-C3 expression construct was
obtained from Judith Meinkoth (University of Pennsylvania, Phil-
adelphia, PA). Antibodies to RhoA, Gq, G12, and G13 and the
blocking peptide for the G12 antibody were obtained from Santa
Cruz Biotechnology, and monoclonal anti-hemagglutinin and anti-
myc antibodies were obtained from Zymed Laboratories. Poly-
clonal anti-sera to G12 and G13 were also obtained from Stefan
Offermanns (University of Heidelberg, Heidelberg, Germany).
Polyclonal anti-serum to RGS2 was from David Siderovski (Uni-
versity of North Carolina, Chapel Hill). Polyclonal anti-serum to
Gq was from Tom Gettys (Pennington Biomedical Research
Center, Baton Rouge, LA). Polyconal antiserum to E-cadherin was
from Robert Brackenbury (University of Cincinnati College of
Medicine, Cincinnati).
Adenoviral Infections. Recombinant adenoviruses were constructed
by subcloning human Gq(Q209L), G12(Q231L), G13(Q226L),
hemagglutinin-RGS2 (University of Missouri cDNA Resource,
Rolla, Mo), myc-p115 (gift of Tohru Kosaza, University of Illinois,
Chicago) and myc-p115(E29K) (generated by site-directed mu-
tagenesis of the myc-p115) into the Adtrack-CMV vector (gift of
Robert Weinberg, The Johns Hopkins University Medical Center)
then recombining these with pAdEasy-1 in BJ5183 Escherichia coli
(Stratagene). The resulting DNA was transfected into HEK 293
cells with Lipofectamine (Invitrogen), then the viruses were serially
amplified and purified with Adeno-X Virus Purification kits (BD
Biosciences). Cell lines were infected at a multiplicity of infection
of 5–50, for 6–24 h at 37°C. Infection efficiencies ranged from
80–100%. For experiments using C3 toxin, 1 mg of purified C3 and
20 hemolytic units (as defined by Biomol) of tetanolysin were added
to the cells for 1 h after the infection media was removed. The cells
were then washed twice with PBS and then were incubated for 18 h
in DMEM with 0.1% fatty-acid-free BSA.
Retrovirus Production. Recombinant retroviruses were constructed
by subcloning human Gq(Q209L), G12(Q231L), G13(Q226L),
hemagglutinin-RGS2 (University of Missouri cDNA Resource),
myc-p115, and myc-p115RGS(E29K) into the pLXRN vector
(Clontech) and pGL-2 firefly luciferase into pLPCX (Clontech).
Constructs were then cotransfected into the GP2–293 packaging
line (Clontech) with FuGene (Roche Applied Science). Viral
supernatants were collected 48 h later, clarified by filtration, and
concentrated by ultracentrifugation. The concentrated virus was
used to infect 1  106 cells in a 60-mm dish with 8 gml polybrene.
4T1 cells were selected with 2 gml puromycin (Sigma) and 1.2
mgml Geneticin (GIBCO). MDA-MB-231 and PC3 cells were
selected with 2 gml puromycin (Sigma) and 800 mgml Geneticin
(GIBCO).
Table 1. Distribution of breat speciman subtypes by G12 staining
Specimen N
Staining intensity
0 1 2 3 Avg.  SEM
Benign breast epithelium 39 5 19 9 2 1.2  0.1
Ductal carcinoma in situ 6 0 2 0 4 2.3  0.4*
Invasive lobular carcinoma 40 1 10 15 15 2.1  0.1**
*, P  0.05 for ductal carcinoma in situ vs. benign breast epithelium. **, P  0.0001 for invasive lobular
carcinoma vs. benign breast epithelium. Avg., average.











Cell Invasion Assay. For invasion assays, transwell chamber filters
(8-m pore size, polycarbonate filter, 6.5-mm diameter; Costar)
were coated with 50 g of growth-factor-reduced Matrigel
(T47D, MDA-MB-231, and BT549) or 20 g of collagen (4T1).
After infection with adenovirus, cells were starved for 18 h in
DMEM containing 0.1% BSA and detached, and 3  105 cells
in 100 l were placed to the upper chamber of the transwell with
and without agonists. The insert was then transferred to a well
containing 600 l of 5 gml of fibronectin in conditioned media
from NIH 3T3. Cells were incubated for 30 h at 37°C in a
humidified incubator. Cells in the top well were removed by
swiping the top of the membrane with cotton swabs. The
membranes were then stained (Hema3 staining kit, Fisher
Scientific), and the remaining cells were counted. Five high-
powered fields were counted for each membrane.
Rho Activity Assays. The levels of activated Rho were determined by
using pull-down assays with a GST fusion of the RhoA-binding
domain of rhotekin as described in ref. 21.
In Vivo Metastasis. Animal handling and procedures were approved
by the Duke University Medical Center Institutional Animal Care
and Use Committee. 4T1 cells expressing firefly luciferase (4T1-
Luc) were generated by retroviral transduction. For mammary fat
pad injections, 5  105 4T1-Luc cells were implanted in the right
axillary mammary fat pad of 6-week-old female BALBc mice. The
volume of the primary tumors was quantified with caliper mea-
surements in three dimensions. At day 21, the primary tumors were
removed as described in ref. 26. Bioluminescence imaging was
performed on all of the mice at 3-day intervals.
For direct metastasis to the lung, 1  105 4T1-Luc cells were
injected into the lateral tail vein of 6-week-old female BALBc
mice. Bioluminescence imaging was performed on all of the mice
at 3-day intervals.
Bioluminescence Imaging. Mice were anesthetized and given 150
gg D-luciferin in PBS by i.p. injection. Fifteen minutes after
injection, bioluminescence was imaged with a charge-coupled de-
vice camera (IVIS; Xenogen, Alameda, CA). Bioluminescence
images were obtained with a 15-cm field of view, binning (resolu-
tion) factor of 8, 1f stop, open filter, and with an imaging time of
30 sec. Bioluminescence from relative optical intensity was defined
manually, and data were expressed as photon flux (photonss per
cm2steradian). Background photon flux was defined from a rel-
ative optical intensity drawn over a mouse that was not given an
injection of luciferin.
Immunohistochemistry. Institutional Review Board-approved breast
samples were from Ardais (Lexington, MA). Tissue microarray
(#BR801) was from U.S. Biomax (Rockville, MD). After paraffin
removal and quenching of endogenous peroxidase, 5-m sections
were steamed in 10 mM citrate, pH 6.0, for 15 min in a steamer
(model no. HS900, Black & Decker), then incubated with Back-
ground Buster (Innovex Biosci, Richmond, CA) for 30 min. Sec-
tions were then incubated with G12 antisera (Santa Cruz Biotech-
nology) diluted 1:100 in PBS for 1 h, followed by biotinylated goat
anti-rabbit antisera (Vector Laboratories, Burlingame, CA) diluted
1:200 in PBS for 30 min, followed by horseradish peroxidase-labeled
streptavidin (Jackson ImmunoResearch) for 30 min, all at room
temperature. Bound immune complex was visualized with DAB
(Innovex Biosci, Richmond, CA); hematoxylin counterstain
(Fisher, Pittsburgh, PA) was used. The G12 staining was graded
0–3 based on intensity, and data were analyzed by using one-way
ANOVA and Dunn’s multiple comparison test in PRISM, Version
4.0c (GraphPad, San Diego).
Supporting Information. Additional details can be found in Sup-
porting Materials and Methods, which is published as supporting
information on the PNAS web site.
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